SCHEMBL937644

SCHEMBL937644

CC(C)NC(=O)c1cccc(-c2cc(-c3ccc(Br)cc3)on2)c1

nearest known ligand 0.67

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.67
RAB9A P51151 4/20 0.67
SMN1; SMN2 Q16637 4/20 0.67
ALDH1A1 P00352 3/20 0.67
HTT P42858 1/20 0.67
PRKD1 Q15139 8/20 0.63
MLLT1 Q03111 1/20 0.52
PRKD3 O94806 1/20 0.52
PRKD2 Q9BZL6 1/20 0.52
TP53 P04637 2/20 0.51
MAPT P10636 1/20 0.51
HPGD P15428 1/20 0.50
ERN1 O75460 1/20 0.48
PPARA Q07869 3/20 0.47
PPARG P37231 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6923851 0.91 PRKD1 (0.63) NPC1RAB9ASMN1; SMN2ALDH1A1HTT
SCHEMBL6922488 0.89 PRKD1 (0.62) NPC1RAB9ASMN1; SMN2ALDH1A1HTT
SCHEMBL966138 0.89 PRKD1 (0.62) NPC1RAB9ASMN1; SMN2ALDH1A1HTT
SCHEMBL6923923 0.85 PRKD1 (0.82) NPC1RAB9ASMN1; SMN2ALDH1A1HTT
SCHEMBL959797 0.85 PRKD1 (0.58) NPC1RAB9ASMN1; SMN2ALDH1A1HTT
SCHEMBL959372 0.84 TP53 (0.65) NPC1RAB9ASMN1; SMN2ALDH1A1HTT
SCHEMBL6923596 0.83 PRKD1 (0.68) NPC1RAB9ASMN1; SMN2ALDH1A1HTT
SCHEMBL957994 0.82 PRKD1 (0.81) ALDH1A1PRKD1PRKD3PRKD2MAPT
SCHEMBL6924477 0.81 PRKD1 (0.56) PRKD1PRKD3PRKD2
SCHEMBL964036 0.81 PRKD1 (0.66) NPC1RAB9ASMN1; SMN2ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011009484-A1 ARYLPYRAZOLES AND ARYLISOXAZOLES AND THEIR USE AS PKD MODULATORS NOVARTIS AG (CH) 2011-01-27 WO disclosed
WO-2011009484-A1 ARYLPYRAZOLES AND ARYLISOXAZOLES AND THEIR USE AS PKD MODULATORS NOVARTIS AG (CH) 2011-01-27 WO disclosed